References
- National Cancer Information Center. National cancer incidence in 2015. Available at: https://www.cancer.go.kr/lay1/S1T639C640/contents.do. Accessed June 11, 2018.
- Yoon JW, Yoo HS, Lee YW, Cho CK. An overview of current oriental medicine herbal cancer research in Korea. Chin J Integr Med 2011 ;17(4):251-6. https://doi.org/10.1007/s11655-011-0710-6
- Park JW, You SJ, Choi SY, Moon G, Lyu YS. Survey of Motives for Visiting Oriental Medical Hospital and Satisfaction with Oriental Medical Care for Cancer Patients: Report of 22 Cases. J of Oriental Neuropsychiatry 2015:26(1):23-38. https://doi.org/10.7231/jon.2015.26.1.023
- Park JS, Yoo HS, Lee YW, Cho JH. Son CG, Cho CK. Wheel Balance Cancer Therapy in the Treatment of Metastatic Gastric carcinoma: A Retrospective Analysis of 62 Patients. Korean J Orient Int Med 2007:28(3):531-43.
- Joo JH. Park SW, Kim SM, Choi HS, Kim KS. Clinical Characteristics Analysis of 58 Patients with Breast and Gynecologic Cancer in Oriental Hospital. J Physiol & Pathol Korean Med 2014:28(5):571-5.
- Jeong TY, Lee YW, Cho CK. Yoo HS. Analysis of Clinical Characteristics for 899 Cancer patients Treated at an Oriental Hospital. Korean J Orient Int Med 2010;31(1):102-12.
- Jeong TY, Park BK. Cho JH, Son CG. Clinical Analysis of 312 Patients with Hepatobiliary Cancer in Oriental Hospital. J Korean Orient Med 2009:30(5):163-73.
- Korean Association of Traditional Oncology textbook compilation committee. Integrative Oncology of Korean Medicine. Seoul: Koonja; 2013, p. 129-31.
- Kang SH, Park YB, Shin HJ. Recent Trends of Research about Immune Checkpoint Inhibitor as Anti-cancer Drug. J Reproductive Med and Population 2015; 28: 63-8.
- Spits H. Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011:12(1): 21-7. https://doi.org/10.1038/ni.1962
- Oken MM, Creech RH. Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. American J of cJinical oncology 1982;5(6):649-55. https://doi.org/10.1097/00000421-198212000-00014
- Vivier E, Raulet D H. Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011:331(6013):44-9. https://doi.org/10.1126/science.1198687
- Vivier E. Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nature Reviews Immunology 2012; 12(4): 239-52. https://doi.org/10.1038/nri3174
- Lee SB, Cha J, Kim IK. Yoon JC, Lee HJ, Park SW, et al. A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun 2014;445(3):584-90. https://doi.org/10.1016/j.bbrc.2014.02.040
- Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 2016; 41:23-31. https://doi.org/10.1016/j.coi.2016.05.006
- Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013:39(1):74-88. https://doi.org/10.1016/j.immuni.2013.06.014
- Sung MW, Johnson JT, Dongen G Van, Whiteside TL. Protective effects of interferon-gamma on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells. Int J Cancer 1996;66(3):393-9. https://doi.org/10.1002/(SICI)1097-0215(19960503)66:3<393::AID-IJC21>3.0.CO;2-B
- Li Y, Yin J, Li T, Huang S, Yan H. Leavenworth J, et al. NK cell-based cancer immunotherapy: from basic biology to clinical application. Science China Life Sciences 2015;58(12):1233-45. https://doi.org/10.1007/s11427-015-4970-9
- Konjevic G, Spuzic I. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma 1993:40(2):81-5
- Tarle M, Kraljic I. Kastelan M. Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data. Urol Res 1993; 21 (1): 17-21. https://doi.org/10.1007/BF00295186
- Jung YS, Kwon MJ, Park DI, Sohn CI, Park JH. Association Between Natural Killer Cell Activity and the Risk of Colorectal Neoplasia. J Gastroenterology & Hepatology 2018;33(4): 831-6. https://doi.org/10.1111/jgh.14028
- Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. American J Gastroenterol 2001:93(2):574-8.
- Hoshikawa M, Aoki T, Matsushita H. Karasaki T, Hosoi A, Odaira K. et al. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun 2018; 495(2): 2058-65. https://doi.org/10.1016/j.bbrc.2017.12.083
- Lee JM, Park KH, Ryu JH. Bae HJ, Choi AR. Lee HY, et al. Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer. Oncotarget 2017:8(41):70431-40.
- Jeong TY. Lee YW. Cho CK. Yoo HS. Analysis of Clinical Characteristics for 899 Cancer Patients Treated at an Oriental Hospital. Korean J Orient Int Med 2010:31(1):102-12.